BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$314.94 USD
+4.91 (1.58%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $315.00 +0.06 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum D VGM
Income Statements
Fiscal Year end for BioRad Laboratories, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,671 | 2,802 | 2,923 | 2,546 | 2,312 |
Cost Of Goods | 1,244 | 1,235 | 1,282 | 1,108 | 1,055 |
Gross Profit | 1,427 | 1,567 | 1,641 | 1,438 | 1,257 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,089 | 1,085 | 1,151 | 1,027 | 1,027 |
Income After Depreciation & Amortization | 338 | 483 | 489 | 411 | 230 |
Non-Operating Income | -1,138 | -5,149 | 4,950 | 4,519 | 2,055 |
Interest Expense | 49 | 38 | 2 | 22 | 23 |
Pretax Income | -850 | -4,704 | 5,438 | 4,908 | 2,261 |
Income Taxes | -213 | -1,077 | 1,192 | 1,101 | 502 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -637 | -3,628 | 4,246 | 3,806 | 1,759 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -637 | -3,628 | 4,246 | 3,806 | 1,759 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 338 | 483 | 489 | 411 | 230 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 338 | 483 | 489 | 411 | 230 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 29.21 | 29.79 | 30.21 | 30.16 | 30.18 |
Diluted EPS Before Non-Recurring Items | 11.78 | 14.42 | 15.66 | 10.52 | 7.06 |
Diluted Net EPS (GAAP) | -21.82 | -121.79 | 140.56 | 126.20 | 58.27 |
Fiscal Year end for BioRad Laboratories, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 638.48 | 610.82 | 681.18 | 632.12 | 681.11 |
Cost Of Goods | 283.36 | 284.85 | 314.82 | 296.44 | 318.63 |
Gross Profit | 355.12 | 325.97 | 366.36 | 335.68 | 362.48 |
SG&A, R&D, and Dept/Amort Expenses | 253.62 | 281.26 | 271.05 | 244.74 | 272.86 |
Income After SG&A, R&D, and Dept/Amort Expenses | 101.50 | 44.71 | 95.31 | 90.94 | 89.62 |
Non-Operating Income | -2,875.51 | 458.65 | 345.44 | 58.55 | -1,577.70 |
Interest Expense | 12.26 | 12.28 | 12.36 | 12.40 | 12.34 |
Pretax Income | -2,786.28 | 491.08 | 428.39 | 137.10 | -1,500.43 |
Income Taxes | -620.80 | 107.16 | 78.68 | 30.85 | -338.18 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2,165.49 | 383.92 | 349.71 | 106.26 | -1,162.25 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2,165.49 | 383.92 | 349.71 | 106.26 | -1,162.25 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 28.40 | 28.54 | 28.82 | 29.22 | 29.36 |
Diluted EPS Before Non-Recurring Items | 3.11 | 2.29 | 3.10 | 2.33 | 3.00 |
Diluted Net EPS (GAAP) | -76.26 | 13.45 | 11.81 | 3.64 | -39.59 |